Company registration number 08579037 (England and Wales)
DR PAWPAW LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024
PAGES FOR FILING WITH REGISTRAR
DR PAWPAW LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 7
DR PAWPAW LIMITED (REGISTERED NUMBER: 08579037)
BALANCE SHEET
AS AT
31 OCTOBER 2024
31 October 2024
- 1 -
2024
2023
Notes
£
£
£
£
Fixed assets
Intangible assets
3
40,886
50,008
Tangible assets
4
26,724
12,947
67,610
62,955
Current assets
Stocks
1,285,591
2,012,556
Debtors
5
2,457,706
2,257,735
Cash at bank and in hand
60,476
218,852
3,803,773
4,489,143
Creditors: amounts falling due within one year
6
(3,459,367)
(3,688,532)
Net current assets
344,406
800,611
Total assets less current liabilities
412,016
863,566
Creditors: amounts falling due after more than one year
7
(27,168)
(64,731)
Net assets
384,848
798,835
Capital and reserves
Called up share capital
8
925
925
Profit and loss reserves
383,923
797,910
Total equity
384,848
798,835

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 October 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

DR PAWPAW LIMITED (REGISTERED NUMBER: 08579037)
BALANCE SHEET (CONTINUED)
AS AT
31 OCTOBER 2024
31 October 2024
- 2 -
The financial statements were approved by the board of directors and authorised for issue on 5 June 2025 and are signed on its behalf by:
Mr J R Paterson
Director
DR PAWPAW LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024
- 3 -
1
Accounting policies
Company information

Dr PawPaw Limited is a private company limited by shares incorporated in England and Wales. The registered office is Bromley Old Town Hall, 30 Tweedy Road, Bromley, England, BR1 3FE.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £1.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover is recognised at the fair value of consideration received or receivable for the goods provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates. The following criteria must also be met before turnover is recognised:

 

1.3
Research and development expenditure

Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated.

1.4
Intangible fixed assets other than goodwill

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Website development costs
33% of cost per annum
Trademarks
10% of cost per annum
1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings
25% straight line
DR PAWPAW LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
1
Accounting policies
(Continued)
- 4 -

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.6
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

1.7
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.8
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

1.9
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.10
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
23
21
DR PAWPAW LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
- 5 -
3
Intangible fixed assets
Website development costs
Trademarks
Total
£
£
£
Cost
At 1 November 2023
19,201
51,073
70,274
Additions
-
0
745
745
At 31 October 2024
19,201
51,818
71,019
Amortisation and impairment
At 1 November 2023
12,800
7,466
20,266
Amortisation charged for the year
5,108
4,759
9,867
At 31 October 2024
17,908
12,225
30,133
Carrying amount
At 31 October 2024
1,293
39,593
40,886
At 31 October 2023
6,401
43,607
50,008
4
Tangible fixed assets
Fixtures and fittings
£
Cost
At 1 November 2023
15,922
Additions
22,558
At 31 October 2024
38,480
Depreciation and impairment
At 1 November 2023
2,975
Depreciation charged in the year
8,781
At 31 October 2024
11,756
Carrying amount
At 31 October 2024
26,724
At 31 October 2023
12,947
DR PAWPAW LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
- 6 -
5
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
2,268,321
2,161,030
Other debtors
189,385
96,705
2,457,706
2,257,735
6
Creditors: amounts falling due within one year
2024
2023
£
£
Bank loans
40,752
38,838
Trade creditors
1,807,266
1,766,616
Taxation and social security
157,146
173,335
Other creditors
1,454,203
1,709,743
3,459,367
3,688,532
7
Creditors: amounts falling due after more than one year
2024
2023
£
£
Bank loans and overdrafts
27,168
64,731
8
Called up share capital
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
0
925
-
0
925
Class A ordinary shares of 1p each
89,032
0
890
-
0
Class B ordinary shares of 1p each
3,468
0
35
-
0
92,500
925
925
925
DR PAWPAW LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
- 7 -
9
Operating lease commitments
Lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2024
2023
£
£
396,145
38,752
10
Charges

As of 31 October 2024 HSBC UK Bank Plc holds a charge over company's assets.

2024-10-312023-11-01falsefalsefalse05 June 2025CCH SoftwareCCH Accounts Production 2025.100No description of principal activityMrs P PatersonMr J R PatersonMr A MintoS Bishop085790372023-11-012024-10-31085790372024-10-31085790372023-10-3108579037core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-10-3108579037core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2024-10-3108579037core:DevelopmentCostsCapitalisedDevelopmentExpenditure2023-10-3108579037core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2023-10-3108579037core:FurnitureFittings2024-10-3108579037core:FurnitureFittings2023-10-3108579037core:CurrentFinancialInstrumentscore:WithinOneYear2024-10-3108579037core:CurrentFinancialInstrumentscore:WithinOneYear2023-10-3108579037core:Non-currentFinancialInstrumentscore:AfterOneYear2024-10-3108579037core:Non-currentFinancialInstrumentscore:AfterOneYear2023-10-3108579037core:CurrentFinancialInstruments2024-10-3108579037core:CurrentFinancialInstruments2023-10-3108579037core:ShareCapital2024-10-3108579037core:ShareCapital2023-10-3108579037core:RetainedEarningsAccumulatedLosses2024-10-3108579037core:RetainedEarningsAccumulatedLosses2023-10-3108579037core:ShareCapitalOrdinaryShareClass12024-10-3108579037core:ShareCapitalOrdinaryShareClass12023-10-3108579037core:ShareCapitalOrdinaryShareClass22024-10-3108579037core:ShareCapitalOrdinaryShareClass22023-10-3108579037core:ShareCapitalOrdinaryShareClass32024-10-3108579037core:ShareCapitalOrdinaryShareClass32023-10-3108579037core:ShareCapitalOrdinaryShares2024-10-3108579037core:ShareCapitalOrdinaryShares2023-10-3108579037bus:Director22023-11-012024-10-3108579037core:DevelopmentCostsCapitalisedDevelopmentExpenditure2023-11-012024-10-3108579037core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2023-11-012024-10-3108579037core:FurnitureFittings2023-11-012024-10-31085790372022-11-012023-10-3108579037core:DevelopmentCostsCapitalisedDevelopmentExpenditure2023-10-3108579037core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2023-10-31085790372023-10-3108579037core:DevelopmentCostsCapitalisedDevelopmentExpenditurecore:ExternallyAcquiredIntangibleAssets2023-11-012024-10-3108579037core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwillcore:ExternallyAcquiredIntangibleAssets2023-11-012024-10-3108579037core:ExternallyAcquiredIntangibleAssets2023-11-012024-10-3108579037core:FurnitureFittings2023-10-3108579037core:WithinOneYear2024-10-3108579037core:WithinOneYear2023-10-3108579037core:Non-currentFinancialInstruments2024-10-3108579037core:Non-currentFinancialInstruments2023-10-3108579037bus:OrdinaryShareClass12023-11-012024-10-3108579037bus:OrdinaryShareClass22023-11-012024-10-3108579037bus:OrdinaryShareClass32023-11-012024-10-3108579037bus:OrdinaryShareClass12024-10-3108579037bus:OrdinaryShareClass12023-10-3108579037bus:OrdinaryShareClass22024-10-3108579037bus:OrdinaryShareClass22023-10-3108579037bus:OrdinaryShareClass32024-10-3108579037bus:OrdinaryShareClass32023-10-3108579037bus:AllOrdinaryShares2024-10-3108579037bus:AllOrdinaryShares2023-10-3108579037bus:PrivateLimitedCompanyLtd2023-11-012024-10-3108579037bus:SmallCompaniesRegimeForAccounts2023-11-012024-10-3108579037bus:FRS1022023-11-012024-10-3108579037bus:AuditExemptWithAccountantsReport2023-11-012024-10-3108579037bus:Director12023-11-012024-10-3108579037bus:Director32023-11-012024-10-3108579037bus:CompanySecretary12023-11-012024-10-3108579037bus:FullAccounts2023-11-012024-10-31xbrli:purexbrli:sharesiso4217:GBP